ArticleActa parasitologica2026
Ref: Submission ID 0e636778-60d8-4db7-8504-1b5c099437d9 Preliminary In Vitro Evaluation of Dodecyl Trimethylammonium Bromide (DDTAB) as a Selective Inhibitor of Theileria annulata-Infected Lymphocyte Proliferation.
Article in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTropical theileriosis, caused by the protozoan parasite Theileria annulata, is an economically significant constraint to cattle production, with disease control increasingly compromised by emerging resistance to the primary chemotherapeutic agent, buparvaquone. This study aimed to screen candidate compounds for in vitro anti-theilerial activity and host cell safety.
methodsFour compounds - hesperidin methyl chalcone (HMC), p-coumaric acid, dodecyl trimethylammonium bromide (DDTAB), and diclofop-methyl - were evaluated for anti-theilerial activity using a resazurin-based viability assay on a T. annulata-infected bovine lymphocyte cell line. Host cell safety was assessed via cytotoxicity assays on bovine peripheral blood mononuclear cells and haemolytic assays on bovine erythrocytes.
resultsDDTAB, a cationic surfactant, showed the strongest concentration-dependent inhibition among the four (IC₅₀ = 1125.4 μM), while the remaining compounds were substantially weaker (IC₅₀ 3048.2 - 5771.7 μM). All compounds, including DDTAB, showed low host cell toxicity (<19 % cytotoxicity and <6 % haemolysis at 1000 μM), yielding selectivity indices of 13.45 (cytotoxicity) and 4.92 (haemolysis) for DDTAB. These IC₅₀ values are in the micromolar range, and are in a higher range than buparvaquone (low nanomolar) and also higher than DDTAB's previously reported activity against Theileria equi (469.51 nM) from our laboratory.
conclusionDDTAB is not therapeutically potent in absolute terms but represents a preliminary hit compound necessitating mechanistic investigation. The findings alsohighlight the utility of the T. annulata-infected lymphocyte assay for future in vitro drug screening.
Indexed as
Identifiers
42541621What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.